A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

Completed

Plain-English translation of NCT04161495 on ClinicalTrials.gov ↗ · Source last updated September 2025 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(47 sites)

United States

Investigational Site Number 920, Los Angeles, California

Investigational Site Number 921, Los Angeles, California

Investigational Site Number 911, San Diego, California

Investigational Site Number 917, Gainesville, Florida

Investigational Site Number 919, Ann Arbor, Michigan